TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Allumiqs and Prolytix Establish Strategic Partnership to Accelerate Drug Discovery and Development

Thursday, March 14, 2024

Allumiqs and Prolytix have recently announced a long-term strategic partnership focused on providing collaborative and integrated solutions to assist customers in optimizing their drug development pipelines. The aim is to empower customers with bioanalytical solutions, facilitating the progression of drug candidates from early research and development phases through to lot release.

This partnership follows successful joint customer engagements, leveraging Allumiqs' expertise in multiomics and LC-MS/MS solutions alongside Prolytix's focus on large-molecule drug product lifecycle management. Together, they offer comprehensive solutions that enhance efficiency and accelerate progress in drug development.

Allumiqs specializes in providing biological insights and therapeutic characterization in the initial phases of a customer's R&D process. This includes mechanism of action, biomarker identification, and drug product characteristics. Customers then transition seamlessly to Prolytix for subsequent targeted method development, covering stability, potency, and GMP release testing. The partnership aims to provide interconnected solutions and processes, supported by a blended team of experts, reducing complications and risks associated with transferring critical R&D work between vendors.

Allumiqs Corporation, highlighted the shared values with Prolytix and a joint commitment to customer success. He emphasized the partnership's goal of simplifying engagement for customers, providing access to innovation partners at every stage of the drug discovery process.

Prolytix, echoed MacLean's sentiments, emphasizing the partnership's potential to enhance their existing portfolio of products and analytical services. Halverson highlighted the proven success of integrating their expertise and solutions in previous customer engagements, underscoring the partnership's ability to provide a robust scientific platform to optimize biopharma research.

Overall, the partnership between Allumiqs and Prolytix represents a significant step forward in supporting the research, development, and commercialization of IVDs, clinical diagnostics, and large molecule biotherapeutics, promising exciting opportunities for their customers.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit